Tacrolimus News and Research

RSS

Tacrolimus is a drug used to help reduce the risk of rejection by the body of organ and bone marrow transplants.

Survival rates for multivisceral transplants increase with new treatment strategies

Data from the largest single-center experience of adult and pediatric intestinal and multivisceral transplantation show that survival rates have improved with the advent of innovative surgical techniques, novel immunosuppressive protocols and better post-operative management, said researchers at the Thomas E. Starzl Transplantation Institute in a study published in the October issue of Annals of Surgery.

6 Oct 2009

Results from Phase 2 clinical study of LCP-Tacro tablets in stable liver transplant patients announced

LifeCycle Pharma A/S today announced positive results from a completed 12 month extension phase of the Phase 2 clinical study of LCP-Tacro tablets in stable liver transplant patients.

30 Sep 2009

Research study indicates that liver regeneration could affect the metabolism of tacrolimus in LDLT

Several studies have shown that living donor liver transplant (LDLT) recipients required smaller doses of tacrolimus compared with deceased donor liver transplant (DDLT) patients, which indicated that liver regeneration could affect the metabolism of tacrolimus in LDLT.

27 Aug 2009

The extremes of BMI a cause for concern in liver transplantation

A recent study by doctors at the University of Washington explained that patients who are significantly underweight or very severely obese prior to liver transplantation are at increased risk of death following transplantation surgery.

4 Aug 2009

Discovery of new angiogenesis protein - possible cancer drug target

To grow and spread, tumors need new blood vessels, a process called angiogenesis. One growth factor that causes angiogenesis has been identified - vascular endothelial growth factor or VEGF - and drugs to inhibit VEGF are already in use. But not all tumors respond to the therapy initially or over the long term. Thus new growth factors need to be identified to aid in developing the next generation of angiogenesis inhibitors.

9 Jun 2009

Emerging therapies could ease symptoms of Atopic dermatitis

Atopic dermatitis, the common, chronic, inflammatory skin disease marked by red, itchy rashes, has been increasing in prevalence over the past two decades and affects a disproportionate number of children.

5 Mar 2009

Revolutionary technique that could reduce lifelong drugs for transplant patients shows promising findings

Researchers have developed a ground-breaking procedure that could avoid the need for transplant patients to spend the rest of their lives taking a cocktail of drugs to stop their system from rejecting their new organ, according to a series of papers in the August issue of Transplant International.

5 Aug 2008

Cellcept immunosuppressant further linked to birth defects

A new study documents malformations seen in an infant born to a kidney transplant recipient who had taken mycophenolate mofetil (MMF), a widely used immunosuppressant available commercially as Cellcept.

7 Feb 2008

Mild chemo before stem cell transplant causes long-term remission of follicular lymphoma

Treating relapsed follicular lymphoma patients with a milder chemotherapy regimen before they receive a blood stem cell transplant from a donor resulted in long-term complete remission for 45 of 47 patients in a clinical trial, researchers at The University of Texas M. D. Anderson Cancer Center report at the 49th annual meeting of the American Society of Hematology.

10 Dec 2007

Renal transplantation in 1-5 year olds

Garcia, et al reported their experience with renal transplantation in 38 children (40 transplant), ages 1-5 years over a 16 year period.

26 Apr 2007

German scientists synthesize new compound that reduces stroke damage

A group of German scientists has synthesized a new compound that dramatically decreases the damage to neurons in rats demonstrating stroke symptoms.

16 May 2006

Topical therapies show promise for Psoriasis

Psoriasis, a chronic skin condition characterized by thick, red, scaly patches that itch and bleed, not only makes the activities of daily life difficult, but also can affect a person's emotional well being.

6 Mar 2006

American Academy of Dermatology disagrees with eczema medication action taken by FDA

The American Academy of Dermatology (Academy) has issued a statement in response to the U.S. Food and Drug Administration’s (FDA) announcement that a black box warning will be added to the labeling and a medication guide will be distributed for the topical calcineurin inhibitors (TCIs), pimecrolimus and tacrolimus.

23 Jan 2006

Cyclosporine suppresses hepatitis C virus and increases the chance of a sustained virological response after liver transplantation

Liver transplant patients with hepatitis C virus (HCV) achieved significantly better long-term viral response when taking the immunosuppressive agent Cyclosporine along with interferon-ribavirin combination therapy. Cyclosporine also showed efficacy against Hepatitis C virus in vitro.

5 Jan 2006

Study finds benefits, less organ rejection using immunosuppressive combination for heart transplants

A new study led by researchers at the UCLA Heart Transplant Program showed that one particular combination using tacrolimus (TAC or PrografÒ also known as FK506) had significant anti-rejection benefits for heart transplant patients over other combinations.

22 May 2005

Protopic and Elidel may cause cancer

Protopic and Elidel, two treatments for eczema approved in 2000 and 2001, have now been found to cause cancer in three different animal species.

13 Mar 2005

Common clinical problem, Rosacea

A number of clinical symptoms and signs are included under the broad group Rosacea. Facial flushing, the appearance of broken blood vessels and persistent redness of the face, eruption of inflamed spots & pimples, on the face and thickening of the sebaceous glands of the nose, with swelling & congestion in that area.

24 Feb 2005

Novel anti-rejection protocol should allow major improvement efficacy and quality of life after intestinal and multivisceral transplants

Transplant researchers at the University of Pittsburgh's Thomas E. Starzl Transplantation Institute have dramatically improved intestinal transplant graft survival, and reduced rejection and infection rates by successfully using a novel immunosuppression minimization protocol, thus improving patients' overall quality of life and avoiding the use of several anti-rejection drugs, which can cause serious infections and major complications.

13 Dec 2004

Impaired cognitive and motor function following stem cell transplantation for severe blood disorders can improve

Patients who suffer a loss of cognitive and motor function as a result of stem cell transplantation for severe blood disorders are likely to see those functions return to previous levels after one year, according to a new study in the November 15, 2004, issue of Blood, the official journal of the American Society of Hematology.

8 Nov 2004

New combination of drugs results in fewer incidences of rejection in liver transplant patients

“The big advantage [of this combination of drugs] is that the incidence of rejection is significantly decreased,” he says. “These results could change the standard of care for liver transplant recipients.”

23 Sep 2004